Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR) reported positive Phase 2 aleniglipron results, including a placebo-adjusted 15.3% weight loss at 36 weeks (240 mg) and no observed weight-loss plateau. The company holds $1.4 billion in cash and short-term investments, expected to fund operations through end-2028.
Topline ACCESS II 44-week results are expected in Q1 2026 and a Phase 3 program is planned to start in 2H 2026; ACCG-2671 entered Phase 1 with data due 2H 2026.
Positive
- Aleniglipron 240 mg: placebo-adjusted -15.3% weight at 36 weeks
- $1.4 billion cash expected runway through end-2028
- Phase 3 initiation for aleniglipron targeted in 2H 2026
- $100.0 million other license income in Q4 and full-year 2025
Negative
- R&D expense rose to $225.3M in 2025 (+107% vs 2024)
- Net loss widened to $141.2M for full-year 2025
- G&A expense increased to $61.6M in 2025 (+25% vs 2024)
Key Figures
Market Reality Check
Peers on Argus
GPCR was down 3.45% while peers showed mixed moves: ELVN up 3.24%, NUVB down 3.47%, PGEN down 4.00%, AMLX down 3.17%, and TRML flat, pointing to stock-specific factors rather than a broad sector rotation.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Positive | -1.9% | Q3 2025 results and guidance on upcoming aleniglipron and amylin milestones. |
| Aug 06 | Q2 2025 earnings | Positive | -0.7% | Q2 2025 financials and progress toward year-end ACCESS topline data. |
| May 08 | Q1 2025 earnings | Positive | -4.7% | Q1 2025 results and confirmation of fully enrolled ACCESS Phase 2b trials. |
| Feb 27 | FY 2024 results | Positive | +4.1% | Full-year 2024 results and strong cash runway supporting obesity pipeline. |
| Nov 13 | Q3 2024 earnings | Positive | +3.6% | Q3 2024 update with initiation of Phase 2b ACCESS and solid cash balance. |
Earnings updates have generally been framed positively but produced modest, often negative, next-day moves, with only 2 of the last 5 earnings reports seeing positive price reactions.
Over the past year, GPCR’s earnings releases have consistently highlighted progress in its oral obesity pipeline and a strong cash position, from $915.3M in Q3 2024 to $883.5M at 2024 year-end and $836.9M–$799.0M through 2025 quarters. Despite this, shares often reacted mildly or negatively (e.g., moves of -4.66% and -1.88%). Today’s full-year 2025 results extend that narrative with larger R&D investment and a much higher cash balance of $1.4B, building on prior guidance about funding Phase 3 programs.
Historical Comparison
In the past five earnings-related releases, GPCR moved an average of 0.1% the next day, suggesting historically modest stock reactions to financial updates and guidance.
Earnings releases show a steady build in funding capacity and clinical ambition, from cash of $915.3M in Q3 2024 and $883.5M at 2024 year-end to $836.9M and $799.0M through early 2025 and now $1.4B at December 31, 2025, alongside advancement of aleniglipron into Phase 3 planning and first-in-human amylin programs.
Regulatory & Risk Context
The company has an active, effective Form S-3ASR automatic shelf registration filed on 2025-08-06 and expiring on 2028-08-06. Shelf usage count is 0, and no specific capacity amounts are provided in the current context.
Market Pulse Summary
This announcement details robust Phase 2 obesity data for aleniglipron, deepening the pipeline with oral amylin candidates and highlighting a strong cash position of $1.4B projected to fund operations through 2028. Compared with prior earnings releases, it marks a transition from Phase 2 enrollment and topline planning to Phase 3 readiness. Investors may focus on upcoming ACCESS II 44-week data, Phase 3 initiation timing, and how elevated R&D spending shapes future financial results.
Key Terms
phase 2b medical
phase 3 medical
glp-1 receptor agonist medical
amylin receptor agonist medical
single ascending dose (sad) medical
placebo-adjusted medical
end-of-phase 2 meeting regulatory
topline results medical
AI-generated analysis. Not financial advice.
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to
Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026
Aleniglipron Phase 3 initiation expected in 2H 2026
Initial data from the ongoing Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral amylin compound ACCG-3535 expected in 2H 2026
Cash, cash equivalents and short-term investments of
SAN FRANCISCO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
“The obesity market is clearly embracing the introduction of new oral treatment options and Structure Therapeutics is well positioned to capture market share in this important therapeutic area,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “In 2025, we delivered positive Phase 2b 36-week data for aleniglipron and advanced ACCG-2671 our first oral small molecule amylin receptor agonist into the clinic. We completed a
Recent and Upcoming Milestones
Aleniglipron - Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight
As reported in December 2025, data from the aleniglipron clinical program included 36-week data from the core Phase 2b ACCESS study and the exploratory ACCESS II study, as well as interim data from the Phase 2 body composition study and the Phase 2b ACCESS open label extension (OLE) study.
- The Phase 2b ACCESS study demonstrated a placebo-adjusted mean weight loss of
11.3% with the 120 mg dose at 36 weeks. No plateau of weight loss was observed. - The exploratory ACCESS II study with higher doses of 180 mg and 240 mg demonstrated a placebo-adjusted mean weight loss of
15.3% with the 240 mg dose at 36 weeks. No plateau of weight loss was observed. - No adverse event-related treatment discontinuations were observed when utilizing the new lower starting titration dose of 2.5 mg in the ACCESS OLE and the Body Composition studies.
Data from the ACCESS, ACCESS II, Body Composition, and the ACCESS OLE studies provide a strong foundation for the decision to advance aleniglipron into Phase 3 clinical development. The Company expects to report topline results from the ACCESS II 44-week study in Q1 2026.
The Company has planned an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to align on a Phase 3 registrational program with a starting titration dose of 2.5 mg and the intent to evaluate multiple maintenance doses. The Company anticipates initiating the Phase 3 program in the second half of 2026.
Supplementary studies enhance competitive profile of aleniglipron:
- Ongoing ACCESS OLE study to evaluate the tolerability of the 2.5 mg starting titration dose regimen for those participants rolling over from the placebo arm and to collect up to 72 weeks of data.
- Ongoing study to assess the transition from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance. This study assesses different aleniglipron starting doses and weight loss maintenance over 12 weeks.
- Ongoing body composition study to assess the effect of aleniglipron on body fat loss over a 40-week evaluation period, which includes a 28-week titration period and a starting dose of 2.5 mg. These data will be used to inform the inclusion of potential body composition endpoints and the appropriate number of participants for a sub-study within the Phase 3 program.
- Ongoing 38-week study in patients with type 2 diabetes mellitus (T2DM) with obesity/overweight to evaluate the potential for including participants with T2DM in the Phase 3 obesity program.
Oral Small Molecule Amylin Receptor Agonists
- In December 2025, Structure Therapeutics advanced ACCG-2671 into a Phase 1 clinical study as the industry’s most advanced oral small molecule amylin therapy for the treatment of obesity. ACCG-2671 is being evaluated in an ongoing single ascending dose (SAD) study to measure safety, tolerability, pharmacokinetics, and food-effect of single ascending doses of ACCG-2671 in healthy adult participants. Data are anticipated in the second half of 2026.
- Structure Therapeutics declared a second oral small molecule dual amylin calcitonin receptor agonist development candidate, ACCG-3535. ACCG-3535, which has a unique chemical structure compared to ACCG-2671, demonstrated robust food intake suppression and significant, dose-dependent body weight reduction as a monotherapy in diet-induced obese rats. Combination therapy with semaglutide (both concurrently and as a subsequent add-on to semaglutide) resulted in superior weight loss compared to semaglutide or ACCG-3535 monotherapy. Structure Therapeutics expects to initiate a Phase 1 clinical study of ACCG-3535 in the second half of 2026.
Fourth Quarter and Full Year 2025 Financial Highlights
Cash Position: Cash, cash equivalents and short-term investments totaled
Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2025 were
General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2025 were
Other license income: Other license income was
Gains on sale of non-financial assets: Gains on sale of non-financial assets was
Net Income/Loss: Net income for the fourth quarter of 2025 totaled
About Aleniglipron and Structure Therapeutics’ Oral Metabolic Franchise
Aleniglipron (GSBR-1290) is an investigational oral small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of obesity and T2DM. Through Structure Therapeutics’ structure-based drug discovery platform, aleniglipron was designed to be a biased G Protein-Coupled Receptor (GPCR) agonist, which selectively activates the G-protein signaling pathway. Beyond aleniglipron, Structure Therapeutics is developing next generation oral small molecules including amylin receptor agonists (ACCG-2671 and ACCG-3535), and other combination GLP-1 receptor agonists candidates targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon and apelin receptors.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Forward- Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; the expected timing of topline data readouts from the ACCESS II study; the planned initiation of the aleniglipron Phase 3 study and the timing thereof; the expected timing of initial data from the Phase 1 study of ACCG-2671; the Company’s anticipated cash runway and uses of cash; the belief that aleniglipron represents a potentially best-in-class small molecule GLP-1; the belief in market acceptance of oral treatment options for metabolic diseases and that Structure Therapeutics is well positioned; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron; plans and the expected timing for the meeting with the FDA to finalize the Phase 3 trial design and the Phase 3 program initiation of aleniglipron; the planned initiation of the Phase 1 clinical study of ACCG-3535 and the timing thereof; and any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials. In addition, when or if used in this press release, the words and phrases “anticipated,” “believe,” “expect,” “plan,” “potential,” “to be,” “will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to topline results that the Company reports are based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial, the preliminary nature of the results due to the length of the study and sample size and the results from earlier clinical studies not necessarily being predictive of future results; potential delays in the commencement, enrollment and completion of the Company’s planned clinical studies; the Company’s ability to advance aleniglipron, ACCG-2671, ANPA-0073, LTSE-2578, ACCG-3535, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company’s therapeutic candidates; competitive products or approaches limiting the commercial value of the Company’s product candidates; the timing and results of preclinical and clinical studies; the Company’s ability to fund development activities and achieve development goals; the Company's reliance on third parties, including clinical research organizations, manufacturers, suppliers and collaborators, over which it may not always have full control; general geopolitical and macroeconomic conditions, including as a result of tariffs and various global conflicts; the Company’s ability to protect its intellectual property; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
Jun Yoon
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
| STRUCTURE THERAPEUTICS INC. Condensed Consolidated Statements of Operations (unaudited) (In thousands) | |||||||||||||||
| THREE MONTHS ENDED | YEAR ENDED | ||||||||||||||
| DECEMBER 31, | DECEMBER 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Operating expenses (income): | |||||||||||||||
| Research and development | $ | 68,689 | $ | 33,487 | $ | 225,255 | $ | 108,814 | |||||||
| General and administrative | 17,571 | 13,574 | 61,554 | 49,414 | |||||||||||
| Other license income | (100,000 | ) | — | (100,000 | ) | — | |||||||||
| Gains on sale of non-financial assets | (10,249 | ) | — | (10,249 | ) | — | |||||||||
| Total operating (income) expenses | (23,989 | ) | 47,061 | 176,560 | 158,228 | ||||||||||
| Income (loss) from operations | 23,989 | (47,061 | ) | (176,560 | ) | (158,228 | ) | ||||||||
| Interest and other income, net | 9,185 | 10,718 | 35,873 | 36,012 | |||||||||||
| Income (loss) before provision for income taxes | 33,174 | (36,343 | ) | (140,687 | ) | (122,216 | ) | ||||||||
| Provision for income taxes | 170 | 136 | 515 | 310 | |||||||||||
| Net income (loss) | $ | 33,004 | $ | (36,479 | ) | $ | (141,202 | ) | $ | (122,526 | ) | ||||
| STRUCTURE THERAPEUTICS INC. Condensed Consolidated Balance Sheet Data (unaudited) (In thousands) | |||||||
| DECEMBER 31, | |||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash, cash equivalents and short-term investments | $ | 1,446,197 | $ | 883,518 | |||
| Prepaid expenses and other current assets | 124,106 | 7,693 | |||||
| Total current assets | 1,570,303 | 891,211 | |||||
| Property and equipment, net | 6,653 | 3,478 | |||||
| Operating right-of-use assets | 6,245 | 3,535 | |||||
| Other non-current assets | 717 | 5,106 | |||||
| Total assets | $ | 1,583,918 | $ | 903,330 | |||
| Liabilities and shareholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 13,864 | $ | 8,024 | |||
| Accrued expenses and other current liabilities | 46,543 | 26,299 | |||||
| Operating lease liabilities, current portion | 2,878 | 1,698 | |||||
| Total current liabilities | 63,285 | 36,021 | |||||
| Operating lease liabilities, net of current portion | 3,609 | 2,164 | |||||
| Other non-current liabilities | 647 | 302 | |||||
| Total liabilities | 67,541 | 38,487 | |||||
| Total shareholders’ equity | 1,516,377 | 864,843 | |||||
| Total liabilities and shareholders’ equity | $ | 1,583,918 | $ | 903,330 | |||
FAQ
What did Structure Therapeutics (GPCR) report about aleniglipron weight loss in Q4 2025?
How long will Structure Therapeutics (GPCR) cash support operations after the Feb 26, 2026 report?
When does Structure Therapeutics (GPCR) plan to start Phase 3 for aleniglipron?
What milestones are expected in 2026 for Structure Therapeutics (GPCR) oral amylin programs?
How did Structure Therapeutics (GPCR) financials change in 2025 versus 2024?
